Moderna files for full U.S. approval of COVID-19 vaccine

Moderna announced efficacy of more than 90% against all cases of COVID-19 and more than 95% against severe infection six months after second dose. It is planning to request emergency use authorization from FDA in early June for adolescents aged 12 to 17.

Reuters Health